Pasithea Therapeutics Corp. 8-K

What Happened
Pasithea Therapeutics Corp. (KTTA) filed an 8-K on Feb 20, 2026 announcing it received a written notice from Nasdaq’s Listing Qualifications Department that the company is not in compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The notice does not trigger immediate delisting; the company has 180 calendar days — until August 19, 2026 — to regain compliance.

Key Details

• Nasdaq found Pasithea’s closing bid price was below $1.00 for the 30 consecutive business days prior to the notice.
• The company has until August 19, 2026 to cure the deficiency; compliance can be achieved if the closing bid is at or above $1.00 for 10 consecutive business days.
• If still noncompliant after 180 days, Pasithea may be eligible for an additional 180-day period if it meets market value of publicly held shares and other initial listing standards (except the bid price) and notifies Nasdaq of intent to cure (which could include a reverse stock split).
• If Nasdaq determines the company cannot cure the deficiency, it could issue a delisting notice, at which point Pasithea may appeal to a hearings panel. The company said it is monitoring the share price and considering options to regain compliance. The notice does not affect the company’s business operations or SEC reporting obligations.

Why It Matters
A continued failure to meet Nasdaq’s $1.00 bid price could lead to delisting, which would reduce liquidity and could make it harder for retail and institutional investors to buy or sell the stock. Investors should monitor the company’s share price, any announced corporate actions (such as a reverse split) intended to cure the deficiency, and subsequent filings or Nasdaq correspondence for updates.